- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04088227
Effects of Platelet Rich Plasma Injections on Biomarkers After Anterior Cruciate Ligament Tears
Effect of Platelet Rich Plasma Injections on Inflammatory and Chondrodegenerative Biomarkers in Patients With Acute Anterior Cruciate Ligament Tears
A potential long-term consequence of anterior cruciate ligament injuries is the development of post-traumatic osteoarthritis in the years following injury. There are no curative treatments for osteoarthritis, increasing the importance of minimizing the occurrence of post-traumatic osteoarthritis following anterior cruciate ligament injuries. Current literature has begun to indicate that biochemical changes in the knee joint cartilage, such as chondrocyte death, following injury can contribute to the development of post-traumatic osteoarthritis.
The main objective of this study is to determine if an early intervention of joint aspiration and platelet rich plasma injection will positively affect the biomarkers representative of chondral degeneration in patients with anterior cruciate ligament injuries. We hypothesize that the intervention will reduce the volume of inflammatory and chondrodegenerative biomarkers following anterior cruciate ligament injury.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jessi L Truett, MA
- Phone Number: 850-916-8570
- Email: jessica.truett@andrewsref.org
Study Locations
-
-
Florida
-
Gulf Breeze, Florida, United States, 32561
- Recruiting
- Andrews Institute for Orthopaedics & Sports Medicine
-
Contact:
- Jessi Truett, MA
- Phone Number: 850-916-8570
- Email: jessica.truett@andrewsref.org
-
Principal Investigator:
- Adam Anz, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- No history of previous traumatic ipsilateral knee injury
- Bone bruise visualized on MRI
- No clinical evidence of posterior cruciate ligament injury with no more than grade 1 medial or lateral collateral ligament injury
Exclusion Criteria:
- Patients without a palpable knee effusion
- An injury occurring more than 10 days before enrollment
- Previous ipsilateral knee surgery
- Intra-articular cortisone or platelet rich plasma injection into either knee within 3 months of injury
- Participation in another clinical drug trial within the 4 weeks before injury
- A history of any inflammatory disease or immune-comprised
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Group
The control group will have a joint aspiration performed at an initial visit (within the first 10 days after injury), and at the time of surgery (within 4 weeks of injury).
|
Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
Other Names:
|
Experimental: Experimental Group
The experimental group will have a joint aspiration performed at an initial visit (within the first 10 days after injury) and receive an injection of leukocyte poor platelet rich plasma injection in their knee.
At a second visit 5-12 days after the initial visit, the patient will receive a joint aspiration and platelet rich plasma injection.
A final joint aspiration will be performed at the time of surgery (within 4 weeks of injury).
|
Patients will receive platelet rich plasma injection two times prior to surgery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Synovial Interleukin-1 Receptor Antagonist Concentration
Time Frame: Initial visit (within 10 days of injury), second visit (5-12 days after the initial visit), and at the time of surgery (within 4 weeks of injury)
|
The presence of this biomarker in the synovial fluid will be assessed.
|
Initial visit (within 10 days of injury), second visit (5-12 days after the initial visit), and at the time of surgery (within 4 weeks of injury)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in International Knee Documentation Committee Score
Time Frame: Initial visit (within 10 days of injury), second visit (5-12 days after the initial visit), and at the time of surgery (within 4 weeks of injury)
|
This survey assess knee function, symptoms, and sports activities.
The scale scores range from 0-100 with a score of 100 indicating no functional limitations or symptoms.
|
Initial visit (within 10 days of injury), second visit (5-12 days after the initial visit), and at the time of surgery (within 4 weeks of injury)
|
Change in Knee Injury and Osteoarthritis Outcome Score
Time Frame: Initial visit (within 10 days of injury), second visit (5-12 days after the initial visit), and at the time of surgery (within 4 weeks of injury)
|
This survey assess knee pain and function.
The scale scores range from 100 (no symptoms) to zero (extreme symptoms).
|
Initial visit (within 10 days of injury), second visit (5-12 days after the initial visit), and at the time of surgery (within 4 weeks of injury)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adam W Anz, MD, Andrews Institute for Orthopaedics & Sports Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACL-PRP Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anterior Cruciate Ligament Rupture
-
Bezirkskrankenhaus SchwazNot yet recruitingAnterior Cruciate Ligament Rupture | Anterior Cruciate Ligament Reconstruction | Anterior Cruciate Ligament InjuryAustria
-
University of Colorado, DenverChildren's Hospital ColoradoRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearUnited States
-
Karolinska InstitutetRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearSweden
-
Rush University Medical CenterEnrolling by invitationAnterior Cruciate Ligament Rupture | Anterior Cruciate Ligament InjuryUnited States
-
Bahçeşehir UniversityIstanbul University - Cerrahpasa (IUC)CompletedAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearTurkey
-
Miach OrthopaedicsActive, not recruitingAnterior Cruciate Ligament Rupture | Anterior Cruciate Ligament InjuryUnited States
-
University of BathVersus ArthritisRecruitingPost-traumatic Osteoarthritis | Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament Tear | Anterior Cruciate Ligament ReconstructionUnited Kingdom
-
Artromedical Konrad Malinowski ClinicRecruitingAnalysis of Radiological Features of Lateral Femoral Impaction Fracture / Lateral Femoral Notch SignAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearPoland
-
Artromedical Konrad Malinowski ClinicRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearPoland
-
Liverpool University Hospitals NHS Foundation TrustRecruitingAnterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearUnited Kingdom
Clinical Trials on Control Group
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Henan Cancer HospitalRecruitingChemotherapy | Immune Checkpoint Inhibitor | Locally Advanced Gastric CarcinomaChina
-
International University of La RiojaRecruiting
-
Romanian Society of Anesthesia and Intensive CareUniversity of Medicine and Pharmacy "Victor Babes" Timisoara; Timişoara County...Completed
-
The University of Hong Konghong Kong Cancer FundCompletedBreast Cancer | Yoga Therapy | Shoulder Joint Motion | Scar Contracture
-
Physicians Committee for Responsible MedicineMetropolitan Police Department of Washington, D.C.SuspendedDiabetes Mellitus, Type 2 | Overweight | Blood PressureUnited States
-
University of PernambucoUnknown
-
Yonsei UniversityUnknownAdvanced Gastric Cancer | Neoadjuvant Chemotherapy | Palliative ChemotherapyKorea, Republic of
-
Istanbul University - Cerrahpasa (IUC)Active, not recruiting